Replimune's Losses Widen Amid Soaring R&D, SG&A Costs

TL;DR

**REPL is burning cash at an alarming rate, making it a high-risk bet despite promising pipeline candidates.**

AI Summary

Replimune Group, Inc. reported a significant increase in net loss for the three and six months ended September 30, 2025, primarily driven by higher operating expenses. The net loss for the three months ended September 30, 2025, was $83.1 million, up from $53.1 million in the prior year, representing a 56.5% increase. For the six months ended September 30, 2025, the net loss widened to $169.8 million from $106.8 million in 2024, a 58.9% increase. Research and development expenses surged to $57.9 million for the three-month period and $115.7 million for the six-month period in 2025, compared to $43.4 million and $86.4 million respectively in 2024, reflecting increased clinical trial activity for RP1, RP2, and RP3. Selling, general and administrative expenses also rose substantially, reaching $26.4 million for the three months and $59.0 million for the six months ended September 30, 2025, up from $15.5 million and $29.9 million in the corresponding 2024 periods. The company's cash and cash equivalents and short-term investments decreased from $483.8 million as of March 31, 2025, to $323.6 million as of September 30, 2025. Replimune expects its current capital to fund operations for at least 12 months, including potential commercialization of RP1 in advanced melanoma, but acknowledges the need for additional financing to support its long-term development programs.

Why It Matters

Replimune's escalating net losses and increased operating expenses signal a critical juncture for investors, highlighting the substantial capital required for clinical-stage biotechnology. The company's reliance on future financing, despite projecting 12 months of runway, introduces significant risk, especially given the competitive landscape in oncolytic immunotherapies. For employees, continued funding is essential for job security and program advancement, while customers (future patients) depend on successful clinical trials and commercialization. The broader market will watch closely to see if Replimune can translate its R&D investments into viable treatments, impacting investor confidence in the high-risk, high-reward biotech sector.

Risk Assessment

Risk Level: high — Replimune reported an accumulated deficit of $1,118.4 million as of September 30, 2025, and net losses of $83.1 million and $169.8 million for the three and six months ended September 30, 2025, respectively. The company explicitly states it expects to generate operating losses for the foreseeable future and will need additional financing, indicating significant financial uncertainty and a high burn rate.

Analyst Insight

Investors should exercise extreme caution and consider the high capital requirements and significant losses. Monitor upcoming clinical trial results for RP1, RP2, and RP3 closely, as positive data could be a catalyst for future financing and potential commercialization, but be prepared for further dilution or a need for substantial debt.

Financial Highlights

debt To Equity

0.48

revenue

N/A

operating Margin

N/A

total Assets

$389.45M

total Debt

$47.21M

net Income

-$83.1M

eps

N/A

gross Margin

N/A

cash Position

$323.6M

revenue Growth

N/A

Key Numbers

• $83.1M — Net Loss (Q3 2025) (Increased 56.5% from $53.1M in Q3 2024)
• $169.8M — Net Loss (Six Months 2025) (Increased 58.9% from $106.8M in Six Months 2024)
• $115.7M — Research and Development Expenses (Six Months 2025) (Increased from $86.4M in Six Months 2024)
• $59.0M — Selling, General and Administrative Expenses (Six Months 2025) (Increased from $29.9M in Six Months 2024)
• $1,118.4M — Accumulated Deficit (As of September 30, 2025, indicating significant historical losses)
• $323.6M — Cash, Cash Equivalents and Short-term Investments (Decreased from $483.8M as of March 31, 2025)
• 78,443,334 — Common Stock Shares Outstanding (As of November 3, 2025)

Key Players & Entities

• Replimune Group, Inc. (company) — clinical-stage biotechnology company
• RP1 (company) — oncolytic immunotherapy product candidate
• RP2 (company) — oncolytic immunotherapy product candidate
• RP3 (company) — oncolytic immunotherapy product candidate
• The Nasdaq Stock Market LLC (regulator) — exchange where common stock is registered
• Securities and Exchange Commission (regulator) — regulatory body for filings
• Financial Accounting Standards Board (regulator) — issuer of accounting standards
• Bloomberg (company) — financial news organization

FAQ

Risk Factors

• Significant Accumulated Deficit [high — financial]: The company has accumulated a deficit of $1,118.4 million as of September 30, 2025. This indicates a history of net losses, which is common for biotechnology companies investing heavily in R&D, but highlights the ongoing need for substantial funding to reach profitability.
• Declining Cash Position [high — financial]: Cash, cash equivalents, and short-term investments decreased from $483.8 million as of March 31, 2025, to $323.6 million as of September 30, 2025. This 33.1% reduction in liquid assets, coupled with increasing operating expenses, raises concerns about the company's ability to fund its long-term development programs without additional financing.
• High and Increasing Operating Expenses [high — operational]: Total operating expenses surged by 43.1% to $84.3 million for the three months ended September 30, 2025, and by 49.4% to $174.7 million for the six months ended September 30, 2025. This increase is primarily driven by R&D and SG&A costs, reflecting significant investment in clinical trials for RP1, RP2, and RP3.
• Clinical Trial and Regulatory Approval Risks [high — regulatory]: The company's success is contingent on the successful development and regulatory approval of its product candidates, including RP1, RP2, and RP3. Delays or failures in clinical trials or the regulatory approval process can significantly impact future revenue and profitability.
• Competition in Oncology Market [medium — market]: Replimune operates in the highly competitive oncology market. The success of its product candidates will depend on their ability to demonstrate superior efficacy and safety compared to existing and emerging therapies.
• Need for Future Financing [high — financial]: The company explicitly states its current capital is expected to fund operations for at least 12 months but acknowledges the need for additional financing to support long-term development programs. Failure to secure this financing could impede the advancement of its pipeline.

Industry Context

Replimune operates in the highly competitive and rapidly evolving immuno-oncology space. The industry is characterized by significant R&D investment, long development cycles, and a high rate of innovation. Key trends include the development of novel therapeutic modalities, combination therapies, and personalized medicine approaches to treat various cancers.

Regulatory Implications

The company's product candidates, RP1, RP2, and RP3, are subject to rigorous review by regulatory bodies like the FDA. Any delays, setbacks, or failures in clinical trials or the approval process pose significant risks to the company's development timeline and commercialization prospects.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Glossary

Accumulated deficit

The cumulative net losses of a company since its inception, minus any net profits. It represents the total loss that has not been offset by profits. (Indicates the company's historical unprofitability and reliance on external funding to cover ongoing operational costs.)

Research and development incentives receivable

Amounts due to the company from government grants or other programs designed to incentivize research and development activities. (Represents a form of non-dilutive funding or reimbursement that can offset R&D expenses.)

Right-of-use asset

An asset representing a lessee's right to use an underlying asset for the lease term, recognized under ASC 842 for operating and financing leases. (Reflects the company's obligations related to leased property and equipment, impacting its balance sheet and cash flows.)

Common stock shares outstanding

The total number of shares of a company's common stock that are held by all its shareholders, including shares held by institutional investors and restricted shares. (A key metric for calculating per-share values (like EPS, though not applicable here due to losses) and for understanding the company's market capitalization.)

Year-Over-Year Comparison

Replimune Group, Inc. reported a significant increase in net loss for the three and six months ended September 30, 2025, compared to the prior year. Total operating expenses rose substantially, driven by a 33.1% increase in R&D expenses and a 71.3% increase in SG&A expenses for the six-month period. Consequently, the net loss widened by 56.5% and 58.9% for the respective periods. The company's cash position also saw a notable decrease of 33.1% from March 31, 2025, to September 30, 2025, highlighting increased cash burn.

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share REPL The Nasdaq Stock Market

Filing Documents

• repl-20250930.htm (10-Q) — 1477KB
• repl-9302025x10qxex311.htm (EX-31.1) — 11KB
• repl-9302025x10qxex312.htm (EX-31.2) — 10KB
• repl-9302025x10qxex321.htm (EX-32.1) — 5KB
• repl-9302025x10qxex322.htm (EX-32.2) — 5KB
• 0001628280-25-049884.txt ( ) — 7431KB
• repl-20250930.xsd (EX-101.SCH) — 58KB
• repl-20250930_cal.xml (EX-101.CAL) — 84KB
• repl-20250930_def.xml (EX-101.DEF) — 215KB
• repl-20250930_lab.xml (EX-101.LAB) — 687KB
• repl-20250930_pre.xml (EX-101.PRE) — 470KB
• repl-20250930_htm.xml (XML) — 968KB

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION 3 Item 1. Condensed Consolidated Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Loss 5 Condensed Consolidated Statements of Stockholders' Equity 6 Condensed Consolidated Statements of Cash Flows 7 Notes to Unaudited Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 40 Item 4.

Controls and Procedures

Controls and Procedures 40

OTHER INFORMATION

PART II OTHER INFORMATION 42 Item 1.

Legal Proceedings

Legal Proceedings 42 Item 1A.

Risk Factors

Risk Factors 42 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 80 Item 3. Defaults Upon Senior Securities 80 Item 4. Mine Safety Disclosure 80 Item 5. Other Information 80 Item 6. Exhibits 81

SIGNATURES

SIGNATURES 82 2 Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. REPLIMUNE GROUP, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands, except share and per share amounts) (Unaudited) September 30, 2025 March 31, 2025 Assets Current assets: Cash and cash equivalents $ 102,298 $ 111,119 Short-term investments 221,346 372,685 Research and development incentives receivable 1,806 3,725 Prepaid expenses and other current assets 8,299 8,351 Total current assets 333,749 495,880 Property, plant and equipment, net 14,711 13,739 Research and development incentives receivable, non-current 799 — Restricted cash 1,705 1,703 Other non-current assets 1,200 1,200 Right-of-use asset - operating leases 3,692 3,998 Right-of-use asset - financing leases 33,594 34,808 Total assets $ 389,450 $ 551,328 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 6,404 $ 12,463 Accrued expenses and other current liabilities 42,445 45,916 Operating lease liabilities, current 1,210 1,184 Financing lease liabilities, current 2,841 2,799 Total current liabilities 52,900 62,362 Operating lease liabilities, non-current 2,723 3,076 Financing lease liabilities, non-current 22,344 22,729 Long term debt, net of discount 47,206 46,377 Other liabilities, non-current 941 941 Total liabilities $ 126,114 $ 135,485 Commitments and contingencies (Note 14) Stockholders' equity Common stock, $ 0.001 par value; 150,000,000 shares authorized as of September 30, 2025 and March 31, 2025 ; 78,403,255 and 77,085,024 shares issued and outstanding as of September 30, 2025 and March 31, 2025, respectively 78 77 Additional paid-in capital 1,376,507 1,358,897 Accumulated deficit ( 1,118,372 ) ( 948,579 ) Accumulated other comprehensive income 5,123 5,448 Total stockholders' equity 263,336 415,843 Total liabilities and stockholders' equity $ 389,450 $ 551,328 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Table of Contents